DDInter1042 DDInter1043
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Levacetylmethadol {u} (Compound) resembles {v} (Compound) Disopyramide
Levacetylmethadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Levacetylmethadol {u} (Compound) binds {v} (Gene) CYP19A1
Levacetylmethadol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Levacetylmethadol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Levacetylmethadol {u} may lead to a major life threatening interaction when taken with {v} Alvimopan
Levacetylmethadol {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Levacetylmethadol {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenoxylate
Levacetylmethadol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Doxylamine
Levacetylmethadol (Compound) resembles Disopyramide (Compound)
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Levacetylmethadol (Compound) binds CYP19A1 (Gene)
Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Levacetylmethadol may lead to a major life threatening interaction when taken with Alvimopan
Levacetylmethadol may lead to a major life threatening interaction when taken with Naltrexone
Levacetylmethadol (Compound) resembles Diphenoxylate (Compound) and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate
Levacetylmethadol (Compound) resembles Doxylamine (Compound) and Levacetylmethadol may lead to a major life threatening interaction when taken with Doxylamine